Journal ArticleDOI
Drug repurposing in cancer.
Linda Sleire,Hilde Elise Førde,Inger Anne Netland,Lina Leiss,Bente Sandvei Skeie,Per Øyvind Enger,Per Øyvind Enger +6 more
Reads0
Chats0
TLDR
An overview of promising candidates for drug repurposing in cancer is provided, as well as studies describing the biological mechanisms underlying their anti-neoplastic effects.About:
This article is published in Pharmacological Research.The article was published on 2017-10-01. It has received 226 citations till now. The article focuses on the topics: Drug development & Cancer.read more
Citations
More filters
Metabolic determinants of cancer cell sensitivity to glucose limitation and biguanides
Richard Possemato,Franziska K. Lorbeer,Erol C. Bayraktar,Prathapan Thiru,Burcu Yucel,Timothy C. Wang,Walter W. Chen,Clary B. Clish,David M. Sabatini,Kıvanç Birsoy +9 more
TL;DR: A continuous-flow culture apparatus for maintaining proliferating cells in low-nutrient media for long periods of time is developed and used to undertake competitive proliferation assays, concluding that mtDNA mutations and impaired glucose utilization are potential biomarkers for identifying tumours with increased sensitivity to OXPHOS inhibitors.
Journal ArticleDOI
The updated landscape of tumor microenvironment and drug repurposing.
Ming-Zhu Jin,Weilin Jin +1 more
TL;DR: An updated image of TME with emphasis on hypoxic niche, immune microenvironment, metabolism micro environment, acidic niche, innervated niche, and mechanical microenvironment is presented and conventional drugs including aspirin, celecoxib, β-adrenergic antagonist, metformin, and statin are summarized in new antitumor application.
Journal ArticleDOI
Overcoming cancer therapeutic bottleneck by drug repurposing
TL;DR: This review presents various promising repurposed non-oncology drugs for clinical cancer management and classify these candidates into their proposed administration for either mono- or drug combination therapy.
Journal ArticleDOI
Old Drugs as New Treatments for Neurodegenerative Diseases.
TL;DR: There is an urgent need for new treatments for this kind of disease, since the World Health Organization has predicted that neurodegenerative diseases affecting motor function will become the second-most prevalent cause of death in the next 20 years.
Journal ArticleDOI
Polytherapy and Targeted Cancer Drug Resistance
TL;DR: The diverse and dynamic strategies that cancers use to evade drug response, the promise of upfront combination and intermittent therapies and therapy switching in forestalling resistance, and epigenetic reprogramming to combat resistance are discussed.
References
More filters
Journal ArticleDOI
Role of AMP-activated protein kinase in mechanism of metformin action
Gaochao Zhou,Robert W. Myers,Ying Li,Yuli Chen,Xiaolan Shen,Judy Fenyk-Melody,Margaret Wu,John Ventre,Thomas W. Doebber,Nobuharu Fujii,Nicolas Musi,Michael F. Hirshman,Laurie J. Goodyear,David E. Moller +13 more
TL;DR: It is reported that metformin activates AMPK in hepatocytes; as a result, acetyl-CoA carboxylase (ACC) activity is reduced, fatty acid oxidation is induced, and expression of lipogenic enzymes is suppressed.
Journal ArticleDOI
The TNF and TNF receptor superfamilies: integrating mammalian biology.
TL;DR: The authors regret the inability to cite all of the primary literature contributing to this review due to length considerations, but wish to thank F. Chan, T. Migone, and J. Wang for insightful comments on the manuscript.
Journal ArticleDOI
Can the pharmaceutical industry reduce attrition rates
Ismail Kola,John Landis +1 more
TL;DR: The pharmaceutical industry faces considerable challenges, both politically and fiscally, and the fiscal pressures that face the industry from the perspective of R&D are dealt with.
Journal ArticleDOI
Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial
Bruce Ettinger,Dennis M. Black,Bruce H. Mitlak,Ronald Keith Knickerbocker,Thomas Nickelsen,Harry K. Genant,Claus Christiansen,Pierre D. Delmas,Jose R. Zanchetta,J. A. Stakkestad,Claus C. Glüer,Kathryn A. Krueger,Fredric J. Cohen,Stephen Eckert,Kristine E. Ensrud,Louis V. Avioli,Paul Lips,Steven R. Cummings +17 more
TL;DR: The Multiple Outcomes of Raloxifene Evaluation (MORE) study as mentioned in this paper evaluated the effect of raloxion hydrochloride therapy on risk of vertebral and non-vertebral fractures.
Journal ArticleDOI
How to improve R&D productivity: the pharmaceutical industry's grand challenge
Steven M. Paul,Daniel S. Mytelka,Dunwiddie Christopher T,Charles C. Persinger,Bernard H. Munos,Stacy R. Lindborg,Aaron Leigh Schacht +6 more
TL;DR: A detailed analysis based on comprehensive, recent, industry-wide data is presented to identify the relative contributions of each of the steps in the drug discovery and development process to overall R&D productivity and propose specific strategies that could have the most substantial impact in improving R &D productivity.
Related Papers (5)
Drug repositioning: identifying and developing new uses for existing drugs
Ted T. Ashburn,Karl B. Thor +1 more